Compare ARK Genomic Revolution ETF (ARKG) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Infosys Limited — how do they compare? ARK Genomic Revolution ETF trades at $41.28, while Infosys Limited trades at $11.49 (market cap $45.83B). The key difference: Infosys Limited pays a 4.79% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Infosys Limited nearer its low. Which is the better fit depends on your goals.
| ARKG | INFY | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $20.22 |
52-Week Low | $23.09 | $10.49 |
Market Cap | — | $45.83B |
Enterprise Value | — | $43.05B |
Dividend Yield | — | 4.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
INFY trades at $10.94, down 1.71% for the day, with technical indicators showing a bearish trend. The company maintains strong profitability with 16.44% net margins and 31.57% ROE, though recent earnings show mixed results with one miss and two beats. Recent news highlights INFY's aggressive AI partnerships across healthcare, banking, and media sectors, positioning the company for digital transformation leadership.
The stock presents a valuation opportunity with P/E of 13.68 below industry averages, supported by analyst consensus target of $12.14 (11% upside). Key risks include competitive pressures in IT services and potential margin compression from AI investments. Current institutional sentiment leans neutral with 52.5% hold ratings amid transitional business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
